1/9
06:10 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Medium
Report
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
1/8
08:17 am
bcax
Rating for BCAX
Medium
Report
Rating for BCAX
1/8
08:02 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
Medium
Report
Bicara Therapeutics (NASDAQ:BCAX) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
1/8
07:03 am
bcax
Bicara Therapeutics initiated with a Buy at BTIG
Medium
Report
Bicara Therapeutics initiated with a Buy at BTIG
12/19
05:57 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at Mizuho to a "hold" rating.
Low
Report
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at Mizuho to a "hold" rating.
12/19
05:57 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at Mizuho to a "hold" rating.
Low
Report
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at Mizuho to a "hold" rating.
12/18
04:32 am
bcax
Rating for BCAX
Low
Report
Rating for BCAX
12/18
04:32 am
bcax
Rating for BCAX
Low
Report
Rating for BCAX
12/17
04:10 pm
bcax
Bicara Therapeutics initiated with a Neutral at Mizuho
Low
Report
Bicara Therapeutics initiated with a Neutral at Mizuho
12/17
04:10 pm
bcax
Bicara Therapeutics initiated with a Neutral at Mizuho
Low
Report
Bicara Therapeutics initiated with a Neutral at Mizuho
11/11
09:35 am
bcax
Rating for BCAX
Medium
Report
Rating for BCAX
11/11
09:35 am
bcax
Rating for BCAX
Medium
Report
Rating for BCAX
11/10
09:04 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Medium
Report
Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
11/10
09:04 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Medium
Report
Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.